Editas Medicine Statistics
Total Valuation
Editas Medicine has a market cap or net worth of $296.66 million. The enterprise value is $190.31 million.
Important Dates
The last earnings date was Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Editas Medicine has 97.91 million shares outstanding. The number of shares has increased by 11.90% in one year.
| Current Share Class | 97.91M |
| Shares Outstanding | 97.91M |
| Shares Change (YoY) | +11.90% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 0.28% |
| Owned by Institutions (%) | 51.95% |
| Float | 97.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.67 |
| Forward PS | 16.71 |
| PB Ratio | 67.30 |
| P/TBV Ratio | 67.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.22, with a Debt / Equity ratio of 3.92.
| Current Ratio | 3.22 |
| Quick Ratio | 3.17 |
| Debt / Equity | 3.92 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.71 |
Financial Efficiency
Return on equity (ROE) is -326.07% and return on invested capital (ROIC) is -96.55%.
| Return on Equity (ROE) | -326.07% |
| Return on Assets (ROA) | -26.95% |
| Return on Invested Capital (ROIC) | -96.55% |
| Return on Capital Employed (ROCE) | -81.26% |
| Weighted Average Cost of Capital (WACC) | 16.39% |
| Revenue Per Employee | $444,747 |
| Profits Per Employee | -$1.25M |
| Employee Count | 87 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +127.82% in the last 52 weeks. The beta is 2.14, so Editas Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.14 |
| 52-Week Price Change | +127.82% |
| 50-Day Moving Average | 2.70 |
| 200-Day Moving Average | 2.65 |
| Relative Strength Index (RSI) | 52.51 |
| Average Volume (20 Days) | 1,464,040 |
Short Selling Information
The latest short interest is 10.92 million, so 11.15% of the outstanding shares have been sold short.
| Short Interest | 10.92M |
| Short Previous Month | 11.94M |
| Short % of Shares Out | 11.15% |
| Short % of Float | 11.18% |
| Short Ratio (days to cover) | 7.13 |
Income Statement
In the last 12 months, Editas Medicine had revenue of $38.69 million and -$108.95 million in losses. Loss per share was -$1.18.
| Revenue | 38.69M |
| Gross Profit | -42.27M |
| Operating Income | -89.03M |
| Pretax Income | -108.95M |
| Net Income | -108.95M |
| EBITDA | -85.19M |
| EBIT | -89.03M |
| Loss Per Share | -$1.18 |
Full Income StatementBalance Sheet
The company has $123.65 million in cash and $17.30 million in debt, with a net cash position of $106.35 million or $1.09 per share.
| Cash & Cash Equivalents | 123.65M |
| Total Debt | 17.30M |
| Net Cash | 106.35M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 4.41M |
| Book Value Per Share | 0.05 |
| Working Capital | 88.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$140.50 million and capital expenditures -$585,000, giving a free cash flow of -$141.09 million.
| Operating Cash Flow | -140.50M |
| Capital Expenditures | -585,000 |
| Depreciation & Amortization | 3.84M |
| Net Borrowing | n/a |
| Free Cash Flow | -141.09M |
| FCF Per Share | -$1.44 |
Full Cash Flow StatementMargins
Gross margin is -109.24%, with operating and profit margins of -230.09% and -281.59%.
| Gross Margin | -109.24% |
| Operating Margin | -230.09% |
| Pretax Margin | -281.59% |
| Profit Margin | -281.59% |
| EBITDA Margin | -220.16% |
| EBIT Margin | -230.09% |
| FCF Margin | n/a |
Dividends & Yields
Editas Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.90% |
| Shareholder Yield | -11.90% |
| Earnings Yield | -36.73% |
| FCF Yield | -47.56% |
Analyst Forecast
The average price target for Editas Medicine is $5.40, which is 78.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.40 |
| Price Target Difference | 78.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 21.81% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Editas Medicine has an Altman Z-Score of -15.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.61 |
| Piotroski F-Score | 3 |
